

Impact Assessment Head & Neck Cancer Institute of India (Cancare Trust)

Corporate Social Responsibility Project by
Mahindra & Mahindra Ltd.

March 2023

Prepared by,
KPMG Assurance and Consulting Services LLP




Table of Contents

01	Rationale	03
02	About Project	04
03	Benefits to Stakeholders	06
04	Project Journey	07
05	IRECS Evaluation	09
06	Pictures from the Project	10



Rationale

- Head and neck cancers (HNC) refer to a broad range of heterogeneous illnesses that develop in the head and neck area, such as malignancies of the oral cavity, nasopharynx, oropharynx, larynx, and hypopharynx.
- **Sixth most frequent** type of cancer worldwide.
- Around 30% cancers in India are H&N compared to only 4% in US & Europe.
- Habits like Chewing Tobacco which are increasing in India one of the major causes HNCs.
- Socio-economic limitations such as low income, employment conditions, housing which makes cancer care a huge burden, this highlights the need of affordable cancer care institutions.
- Predominant chewing of Gutka, betel, tobacco and alcohol consumption, the leading cause of oral cancers in South-east nations.



CHALLENGES TO CANCER CARE IN INDIA

- Rising Cost of Cancer care because of modern technology which is unaffordable to economically weaker strata of population.
- Lack of healthcare infrastructure which gives strain to currently working hospitals and to reduce this load there is need of other institution which can work in co-ordination with currently working hospitals.
- Lack of trained healthcare professionals leads to delay in treatment thus there is need of more professionals in proportion to cases & there is need to fulfil this requirement.
- For better diagnosis and treatment of HNC, modern technology and precision equipment is required which can result in better cancer care.

About Project



Support

Mahindra and Mahindra Ltd. and Mahindra Foundation partnered with cancare trust towards the building of Head and Neck Cancer Institute of India, Mazgaon, Mumbai.



Established

Head and Neck Cancer Institute of India (HNCII), an initiative of the CanCare trust. Trust's vision is to provide affordable cancer treatment to the public.



Location

Barrister Nath Pai Road, Mazagaon, Mumbai, India



Special Feature


First of its kind in India to provide care for Head & Neck Cancer at affordable rates in Mumbai with very nominal cost of treatments & established in PPP mode with BMC.

Facilities

Hospital with 93 beds capacity and range of facilities including investigative, curative nuclear medicine, diagnostic, radiation and chemotherapy. Modern equipment with facility of reconstruction and re-installation of tissues/organs.

Benefits

- 20% of the institute beds reserved for indigent and weaker section patients who would be provided treatment free or at very nominal charges.
- All treatment costs fixed based on rates of Tata Memorial Cancer Hospital, Parel, which provides heavily subsidized treatment to patients.





Findings from the Impact Assessment




Benefit to Stakeholders

HNCII would cater to shareholders from a wide group of socio-economic strata as well as those who are unable to avail treatment due to any of the mentioned reasons.

Training to be provided for HNC surgeons in Mumbai, thereby, addressing their severe shortfall.

At least 40% reduction in cost of treatment compared to other premier hospitals in the city providing similar kinds of facilities.

State of the art equipment and software to provide the best treatment, Mechanisms for patient mobilization.




Specialized treatment for HNCs; one of the leading cause of cancer in men and the 3rd leading cause of cancer.

The institute to also provide treatment for cancers found in women such as breast, uterus and cervical cancer.

Advanced research laboratories to provide opportunity to train specialists on the latest technology.

Project Journey





IRECS Evaluation



IRECS Evaluation

Inclusiveness

- Highly subsidized care for economically weaker sections with one-fifth beds exclusively reserved for economically weaker sections.
- Dedicated only for HNCs as well as most prevalent cancers in women resulting in inclusion of multiple sections of society.

Sustainability


- The institute has devised strategies for sustenance by establishing costs for different categories of patients.
- Additionally, support from philanthropic organizations as well as utilizing and integrating with government schemes in future would sustain the facility.

01

02

Relevance

- The institute would provide care to the growing burden of HNC worldwide, and specially in India.
- It will also strengthen capacities of HNC surgeons in India on the latest equipment and treatment methods.



03

Effectiveness

- There will be at least a 40% reduction in treatment costs on comparison to private hospitals due to subsidized costs while utilizing state of the art technology and facilities.

04

Convergence

- HNCII has been developed in a PPP collaboration with Municipal Corporation of Greater Mumbai.
- Partnerships have been identified with Tata Memorial Centre, Parel (Mumbai) to increase facility outreach.

05


Photos



Fully developed Operation Theatre at the center



A twin sharing room at the center



Research laboratory at the center

Thank You

Disclaimers:

- This report has been prepared for Mahindra and Mahindra Ltd. ("Client") based on the terms of the Contracts ("Contract") executed between Mahindra and Mahindra Ltd. and KPMG Assurance and Consulting Services LLP ("KPMG" or "we").
- The performance of KPMG's services and the report issued to the Client are based on and subject to the terms of the Contract.
- This report sets forth our views based on the completeness and accuracy of the facts stated to KPMG and any assumptions that were included. If any of the facts and assumptions is not complete or accurate, it is imperative that we be informed accordingly, as the inaccuracy or incompleteness thereof could have a material effect on our conclusions.
- While performing the work, we assumed the genuineness of all signatures and the authenticity of all original documents. We have not independently verified the correctness or authenticity of the same.
- While information obtained from the public domain or external sources has not been verified for authenticity, accuracy or completeness, we have obtained information, as far as possible, from sources generally considered to be reliable. We assume no responsibility for such information.
- Performance of our work was based on information and explanations given to us by the Client. Neither KPMG nor any of its partners, directors or employees undertake responsibility in any way whatsoever to any person in respect of errors in this report, arising from incorrect information provided by the Client.
- Our report may make reference to 'KPMG Analysis'; this indicates only that we have (where specified) undertaken certain analytical activities on the underlying data to arrive at the information presented; we do not accept responsibility for the veracity of the underlying data.
- In accordance with its policy, KPMG advises that neither it nor any of its partner, director or employee undertakes any responsibility arising in any way whatsoever, to any person other than Client in respect of the matters dealt with in this report, including any errors or omissions therein, arising through negligence or otherwise, howsoever caused.
- In connection with our report or any part thereof, KPMG does not owe duty of care (whether in contract or in tort or under statute or otherwise) to any person or party to whom the report is circulated to and KPMG shall not be liable to any party who uses or relies on this report. KPMG thus disclaims all responsibility or liability for any costs, damages, losses, liabilities, expenses incurred by such third party arising out of or in connection with the report or any part thereof.
- By reading our report, the reader of the report shall be deemed to have accepted the terms mentioned hereinabove.